Avacta, Glythera link to develop drug conjugates by Selina McKee | Jan 16, 2018 | News | 0 UK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies. Read More
UK firms link to develop ADCs for cancer by Selina McKee | Sep 20, 2017 | News | 0 UK groups Glythera and IONTAS are working together on the development of antibody drug conjugates for difficult-to-treat cancers. Read More
Glythera launches Innovate UK-funded ADC project by Selina McKee | Jun 6, 2017 | News | 0 UK biotech Glythera has announced the launch of a £1 million Innovate UK grant-funded project to develop next-generation antibody drug conjugates (ADCs) for difficult-to-treat tumours. Read More